EEDi-5285: An Exceptionally Potent, Efficacious, and Orally Active Small-Molecule Inhibitor of Embryonic Ectoderm Development
dc.contributor.author | Rej, RK | |
dc.contributor.author | Wang, C | |
dc.contributor.author | Lu, J | |
dc.contributor.author | Wang, M | |
dc.contributor.author | Petrunak, E | |
dc.contributor.author | Zawacki, KP | |
dc.contributor.author | McEachern, D | |
dc.contributor.author | Fernandez-Salas, E | |
dc.contributor.author | Yang, CY | |
dc.contributor.author | Wang, L | |
dc.contributor.author | Li, R | |
dc.contributor.author | Chinnaswamy, K | |
dc.contributor.author | Wen, B | |
dc.contributor.author | Sun, D | |
dc.contributor.author | Stuckey, J | |
dc.contributor.author | Zhou, Y | |
dc.contributor.author | Chen, J | |
dc.contributor.author | Tang, G | |
dc.contributor.author | Wang, S | |
dc.coverage.spatial | United States | |
dc.date.accessioned | 2022-08-23T19:17:57Z | |
dc.date.available | 2022-08-23T19:17:57Z | |
dc.date.issued | 2020-07-09 | |
dc.identifier.issn | 0022-2623 | |
dc.identifier.issn | 1520-4804 | |
dc.identifier.uri | https://www.ncbi.nlm.nih.gov/pubmed/32580550 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/174124 | en |
dc.description.abstract | Inhibition of embryonic ectoderm development (EED) is a new cancer therapeutic strategy. Herein, we report our discovery of EEDi-5285 as an exceptionally potent, efficacious, and orally active EED inhibitor. EEDi-5285 binds to the EED protein with an IC50 value of 0.2 nM and inhibits cell growth with IC50 values of 20 pM and 0.5 nM in the Pfeiffer and KARPAS422 lymphoma cell lines, respectively, carrying an EZH2 mutation. EEDi-5285 is approximately 100 times more potent than EED226 in binding to EED and >300 times more potent than EED226 in inhibition of cell growth in the KARPAS422 cell line. EEDi-5285 has excellent pharmacokinetics and achieves complete and durable tumor regression in the KARPAS422 xenograft model in mice with oral administration. The cocrystal structure of EEDi-5285 in a complex with EED defines the precise structural basis for their high binding affinity. EEDi-5285 is the most potent and efficacious EED inhibitor reported to date. | |
dc.format.medium | Print-Electronic | |
dc.language | eng | |
dc.publisher | American Chemical Society (ACS) | |
dc.subject | Administration, Oral | |
dc.subject | Animals | |
dc.subject | Antineoplastic Agents | |
dc.subject | Biological Availability | |
dc.subject | Cell Line, Tumor | |
dc.subject | Crystallography, X-Ray | |
dc.subject | Histones | |
dc.subject | Humans | |
dc.subject | Lymphoma | |
dc.subject | Mice, SCID | |
dc.subject | Polycomb Repressive Complex 2 | |
dc.subject | Small Molecule Libraries | |
dc.subject | Structure-Activity Relationship | |
dc.subject | Xenograft Model Antitumor Assays | |
dc.title | EEDi-5285: An Exceptionally Potent, Efficacious, and Orally Active Small-Molecule Inhibitor of Embryonic Ectoderm Development | |
dc.type | Article | |
dc.identifier.pmid | 32580550 | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/174124/2/5285 J. Med. Chem. 2020, 63, 7252−7267.pdf | |
dc.identifier.doi | 10.1021/acs.jmedchem.0c00479 | |
dc.identifier.doi | https://dx.doi.org/10.7302/5855 | |
dc.identifier.source | Journal of Medicinal Chemistry | |
dc.description.version | Published version | |
dc.date.updated | 2022-08-23T19:17:54Z | |
dc.identifier.orcid | 0000-0002-5445-0109 | |
dc.identifier.orcid | 0000-0002-6406-2126 | |
dc.identifier.orcid | 0000-0002-7131-4678 | |
dc.identifier.orcid | 0000-0002-8782-6950 | |
dc.description.filedescription | Description of 5285 J. Med. Chem. 2020, 63, 7252−7267.pdf : Published version | |
dc.identifier.volume | 63 | |
dc.identifier.issue | 13 | |
dc.identifier.startpage | 7252 | |
dc.identifier.endpage | 7267 | |
dc.identifier.name-orcid | Rej, RK | |
dc.identifier.name-orcid | Wang, C | |
dc.identifier.name-orcid | Lu, J | |
dc.identifier.name-orcid | Wang, M | |
dc.identifier.name-orcid | Petrunak, E | |
dc.identifier.name-orcid | Zawacki, KP | |
dc.identifier.name-orcid | McEachern, D | |
dc.identifier.name-orcid | Fernandez-Salas, E | |
dc.identifier.name-orcid | Yang, CY; 0000-0002-5445-0109 | |
dc.identifier.name-orcid | Wang, L | |
dc.identifier.name-orcid | Li, R | |
dc.identifier.name-orcid | Chinnaswamy, K | |
dc.identifier.name-orcid | Wen, B | |
dc.identifier.name-orcid | Sun, D; 0000-0002-6406-2126 | |
dc.identifier.name-orcid | Stuckey, J | |
dc.identifier.name-orcid | Zhou, Y | |
dc.identifier.name-orcid | Chen, J | |
dc.identifier.name-orcid | Tang, G; 0000-0002-7131-4678 | |
dc.identifier.name-orcid | Wang, S; 0000-0002-8782-6950 | |
dc.working.doi | 10.7302/5855 | en |
dc.owningcollname | Internal Medicine, Department of |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.